LIGAND PHARMACEUTICALS INC's ticker is LGND and the CUSIP is 53220K504. A total of 332 filers reported holding LIGAND PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is 2.08 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2021 | $282,000 | -17.8% | 2,151 | -4.4% | 0.00% | -50.0% |
| Q1 2021 | $343,000 | +55.2% | 2,251 | +13.7% | 0.00% | +100.0% |
| Q2 2020 | $221,000 | -47.8% | 1,980 | -51.2% | 0.00% | -50.0% |
| Q4 2019 | $423,000 | -59.8% | 4,060 | -61.6% | 0.00% | -66.7% |
| Q3 2019 | $1,053,000 | -5.8% | 10,580 | +8.1% | 0.01% | 0.0% |
| Q2 2019 | $1,118,000 | -34.3% | 9,790 | -27.7% | 0.01% | -33.3% |
| Q1 2019 | $1,702,000 | +68.8% | 13,540 | +82.4% | 0.01% | +50.0% |
| Q4 2018 | $1,008,000 | -23.7% | 7,425 | +54.3% | 0.01% | -14.3% |
| Q3 2018 | $1,321,000 | +119.8% | 4,811 | +65.8% | 0.01% | +133.3% |
| Q2 2018 | $601,000 | +25.5% | 2,901 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $479,000 | +21.6% | 2,901 | +0.7% | 0.00% | +50.0% |
| Q4 2017 | $394,000 | +71.3% | 2,881 | +70.3% | 0.00% | +100.0% |
| Q3 2017 | $230,000 | +11.1% | 1,692 | -12.3% | 0.00% | -50.0% |
| Q1 2016 | $207,000 | – | 1,929 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Knott David M Jr | 115,000 | $7,682 | 2.90% |
| VILLERE ST DENIS J & CO LLC | 483,347 | $32,287 | 2.52% |
| Monarch Partners Asset Management LLC | 62,327 | $4,163,444 | 1.23% |
| Chicago Capital, LLC | 319,054 | $21,312,820 | 1.18% |
| RICE HALL JAMES & ASSOCIATES, LLC | 285,634 | $19,080,351 | 1.09% |
| Stephens Investment Management Group LLC | 454,416 | $30,713,977 | 0.56% |
| Smith, Graham & Co., Investment Advisors, LP | 65,372 | $4,366,850 | 0.53% |
| WOODSTOCK CORP | 55,014 | $3,674,935 | 0.49% |
| Court Place Advisors, LLC | 15,533 | $1,037,605 | 0.38% |
| ISTHMUS PARTNERS, LLC | 19,830 | $1,324,644 | 0.20% |